Table 2.

Results of the network meta-analysis of the clinical effectiveness rate (upper-right quadrant) and performance status (lower-left quadrant).

AD+RT	0.57 (0.42, 0.78)	3.36 (0.56, 28.18)	1.09 (0.28, 4.38)	3.01 (1.07, 9.15)	1.85 (0.96, 3.65)	1.93 (0.60, 7.05)	2.43 (0.23, 69.2)	1.11 (0.63, 1.98)	2.28 (0.83, 6.71)	1.37 (0.43, 4.55)	1.55 (0.92, 2.56)
0.32 (0.18, 0.56)	RT	5.84 (1.02, 48.01)	1.91 (0.52, 7.45)	5.21 (1.97, 15.43)	3.24 (1.83, 5.90)	3.36 (1.10, 11.84)	4.25 (0.39, 118.3)	1.94 (1.20, 3.20)	4.00 (1.53, 11.18)	2.41 (0.78, 7.57)	2.71 (1.82, 4.05)
–	–	DC+RT	0.32 (0.027, 3.07)	0.90 (0.092, 6.67)	0.55 (0.064, 3.57)	0.58 (0.049, 4.79)	0.72 (0.030, 30.41)	0.32 (0.039, 2.05)	0.69 (0.070, 5.06)	0.41 (0.038, 3.36)	0.46 (0.055, 2.81)
–	–	–	SM+RT	2.79 (0.49, 14.54)	1.69 (0.39, 7.20)	1.80 (0.31, 10.63)	2.25 (0.15, 66.69)	1.01 (0.24, 4.07)	2.09 (0.40, 11.02)	1.27 (0.21, 7.09)	1.41 (0.34, 5.71)
1.54 (0.75, 3.18)	4.84 (3.08, 7.77)	–	–	CKS+RT	0.61 (0.18, 1.99)	0.64 (0.14, 3.05)	0.83 (0.058, 26.34)	0.37 (0.12, 1.10)	0.76 (0.18, 3.09)	0.46 (0.094, 2.04)	0.52 (0.16, 1.48)
–	–	–	–	–	HCS+RT	1.04 (0.29, 4.18)	1.32 (0.12, 39.91)	0.60 (0.28, 1.30)	1.23 (0.40, 4.05)	0.74 (0.20, 2.66)	0.84 (0.41, 1.71)
1.55 (0.39, 6.37)	4.84 (1.40, 18.34)	–	–	0.99 (0.27, 4.06)	–	AP+RT	1.25 (0.090, 39.41)	0.58 (0.15, 1.93)	1.18 (0.25, 5.36)	0.71 (0.14, 3.50)	0.81 (0.21, 2.62)
–	–	–	–	–	–	–	AI+RT	0.45 (0.016, 5.21)	0.93 (0.032, 11.65)	0.56 (0.018, 7.99)	0.63 (0.022, 7.28)
1.19 (0.51, 2.82)	3.75 (1.98, 7.12)	–	–	0.77 (0.35, 1.70)	–	0.77 (0.18, 3.12)	–	KA+RT	2.08 (0.70, 6.34)	1.25 (0.36, 4.34)	1.39 (0.75, 2.65)
–	–	–	–	–	–	–	–	–	EL+RT	0.60 (0.13, 2.60)	0.67 (0.23, 1.92)
1.34 (0.34, 5.68)	4.22 (1.21, 15.97)	–	–	0.87 (0.23, 3.56)	–	0.87 (0.14, 5.34)	–	1.12 (0.27, 4.95)	–	LE+RT	1.13 (0.33, 3.67)
0.74 (0.32, 1.72)	2.33 (1.25, 4.37)	–	–	0.48 (0.22, 1.03)	–	0.48 (0.11, 1.95)	–	0.62 (0.26, 1.51)	–	0.55 (0.13, 2.18)	JOE+RT